← Browse by Condition
Medical Condition

macular degeneration

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2, Phase 3, Phase 1, Phase 2

ClinicalMetric tracks all active clinical trials for macular degeneration sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — macular degeneration Clinical Trials

How many clinical trials are currently recruiting for macular degeneration?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for macular degeneration, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for macular degeneration?
macular degeneration research spans Phase 1 (1 trial), Phase 2 (2 trials), Phase 3 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a macular degeneration clinical trial?
Eligibility criteria for macular degeneration trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 1
1
Phase 2
2
Phase 3
1
Top Sponsors
EyeBiotech Ltd. 1 trial
New England College of Optometry 1 trial
Eyestem Research Pvt. Ltd. 1 trial
University of Waterloo 1 trial

Recruiting Clinical Trials

NCT07496567 Phase 2, Phase 3
Recruiting
A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
Enrollment
960 pts
Location
United States
Sponsor
EyeBiotech Ltd.
View Trial →
NCT07577219
Recruiting
Vision Rehabilitation Training With Multimodal Feedback in Central Vision Loss
Enrollment
12 pts
Location
United States
Sponsor
New England College of Optomet...
View Trial →
NCT06394232 Phase 1, Phase 2
Recruiting
Safety & Efficacy of Eyecyte-RPE™ in Patients With Geographic Atrophy Secondary to Dry Age-related Macular Degeneration.
Enrollment
54 pts
Location
India
Sponsor
Eyestem Research Pvt. Ltd.
View Trial →
NCT04762368
Recruiting
Learning Study: Improving Vision in Adults With Macular Degeneration
Enrollment
30 pts
Location
Canada, Hong Kong
Sponsor
University of Waterloo
View Trial →

Related Conditions

age related macular degeneration (2) choroidal neovascularization (1) wet macular degeneration (1) low vision (1) central visual impairment (1) retinal disease (1) geographic atrophy (1) eye diseases (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology